Regulatory Updates
Page 2 • 12 itemsTrack global pharma regulatory policy changes, FDA, EMA, and other agency guidelines impacting drug development and market access. Stay ahead.
NMPA Priority Review Pathway: Impact on Innovative Drug Approvals in China
The NMPA Priority Review Pathway significantly impacts the approval process for innovative drugs in China, expediting access to critical therapies such as XYZ for cancer patients.
PMDA Approves Peripheral Rotablator PRO and Visual-ICE Cryoablation System Modifications in Japan
Japan's PMDA grants partial change approval for Peripheral Rotablator PRO and Visual-ICE Cryoablation System, expanding cardiovascular treatment options.
NMPA Priority Review Pathway: What You Need to Know About Innovative Drug Approvals
Learn how the NMPA Priority Review Pathway accelerates innovative drug approvals, enhancing access to cutting-edge therapies for patients with critical conditions.
NMPA Expedited Approval Oncology: Impact on Cancer Drug Access in China
The NMPA's expedited approval process is transforming cancer drug access in China, significantly impacting treatments like osimertinib for lung cancer patients.
NMPA Priority Review Granted to AI Diagnostic Tool for Early Cancer Detection
The NMPA has granted priority review to an innovative AI diagnostic tool designed for early cancer detection, promising to revolutionize patient outcomes.
PMDA approves AI-driven platform: What You Need to Know
The PMDA has approved a groundbreaking AI-driven platform, revolutionizing drug development and safety protocols in the pharmaceutical industry.
![NMPA Priority Review Granted to [Drug Name] for Lung Cancer](/uploads/articles/nmpa-priority-review-drugname-lung-cancer-2024.webp)
NMPA Priority Review Granted to [Drug Name] for Lung Cancer
[Drug Name] has received NMPA priority review for lung cancer, potentially revolutionizing patient care and treatment outcomes in this critical area.
![PMDA approves [Drug Name]: Expedited SAKIGAKE approval for [Disease]](/uploads/articles/pmda-approves-[drug-name]-sakigake-[disease]-2024.webp)
PMDA approves [Drug Name]: Expedited SAKIGAKE approval for [Disease]
[Drug Name] has received expedited SAKIGAKE approval from PMDA for the treatment of [Disease], marking a significant advancement in therapeutic options.
NMPA Data Integrity: What Pharmaceutical Manufacturers Must Know
Understanding NMPA data integrity is crucial for pharmaceutical manufacturers to ensure compliance and maintain trust in drug safety and efficacy.
PMDA Accepts Shionogi Novel Influenza Drug with SAKIGAKE Designation
The PMDA has accepted Shionogi's novel influenza drug, recognized with SAKIGAKE designation, marking a significant advancement in flu treatment.
Growth of Generics Market India: Impact of CDSCO Policy Changes on Pricing
This article examines the rapid growth of the generics market in India, highlighting the impact of CDSCO policy changes on drug pricing and accessibility.
PMDA SAKIGAKE Designation: Accelerating Regenerative Medicine Market Access in Japan
Explore the impact of PMDA SAKIGAKE Designation on speeding up access to regenerative medicine in Japan, enhancing treatment options for patients.